Fig.1
PRIOR ART

PRIOR ART

ACTIVITIES
RESOURCES

3b
Sb
OUTPUT ENTITY
9b
11b
11b
11c
11c




Fig.3
PRIOR ART




Fig.4
PRIOR ART

•	INPUT ENTITY	9
	RESOURCES	5_
ACTIVITY (3a)	ACTIVITY	<u>3</u> b
	ACTIVITY	<u>3</u> c
	CONTROL	7

Fig.5





Fig.6

T R






Fig.9

EXERCISE RELATIVE TO BODY SYSTEMS (29)

EXERCISE TYPES OF EXERCISE (31)

EXERCISE RELATIVE TO INPUTS (35)

Fig.10

3b

EXERCISE RELATIVE TO BODY SYSTEM


CARDIOVASCULAR RESPIRATORY MUSCULAR


R


M


M


M















Fig.17

Fig.18










Fig.20












Fig.26







Fig.27

TRIAL HISTORY FOR DRUG DEVELOPMENT (SAMPLE 10) JAN > FEB > MAR > APR > JUNE > JULY > AUG > SEPT > OCT	FROM 1.5 TO 2.3 STARTS AT 1.00	START RANGE GOES FROM 0.1 TO 4.9 IN DATA SET 3.16 AVG RANGES FROM 3 TO 4	START RANGE GOES FROM 1.1 TO 9.2 IN DATA SET [1.27 AVG RANGES FROM STARTS AT 5.83 1.0 TO 2.2	START RANGE GOES FROM 2.3 TO 9.1 IN DATA SET 1.94 AVG RANGES FROM 1.0 TO 3.3	STARTS 6.9
TRIAL	TRIAL A	TRIAL B	TRIAL C	TRIAL D	







PROJECTS A, B, C 1998

WEIGHTED AVERAGE OF LEVEL II = 1.0 LEVEL III = 0.75

OPPORTUNITIES

RISKS






Fig.31

LEVEL 1

LEVEL 2

LEVEL 3






LEVEL 3

LEVEL 2

LEVEL 1

Fig.33



PROJECTS A, B, C 1999

WEIGHTED AVERAGE OF LEVEL II = 1.0 LEVEL III = 0.75

OPPORTUNITIES

RISKS




Fig.35

LEVEL 1

LEVEL 2

LEVEL 3




Fig.37 DS₃ DS₁ DS₂ DS₂ DS_3 DS₄ DŞ₅ DS₄/S₅(T₃ T₂ T₁ 75